11/26
03:14 pm
anab
SA Quant ranks Goldman's small-cap stocks with largest short interest [Seeking Alpha]
Low
Report
SA Quant ranks Goldman's small-cap stocks with largest short interest [Seeking Alpha]
11/25
04:56 pm
anab
Anaptys Announces Participation in December Investor Conferences [Yahoo! Finance]
Low
Report
Anaptys Announces Participation in December Investor Conferences [Yahoo! Finance]
11/25
04:15 pm
anab
Anaptys Announces Participation in December Investor Conferences
Low
Report
Anaptys Announces Participation in December Investor Conferences
11/24
08:43 am
anab
AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $50.00 price target on the stock.
Low
Report
AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $50.00 price target on the stock.
11/24
08:06 am
anab
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $52.00 to $51.00. They now have a "buy" rating on the stock.
Medium
Report
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $52.00 to $51.00. They now have a "buy" rating on the stock.
11/21
07:04 pm
anab
Anaptys Announces $100 Million Stock Repurchase Plan [Yahoo! Finance]
Medium
Report
Anaptys Announces $100 Million Stock Repurchase Plan [Yahoo! Finance]
11/21
09:12 am
anab
AnaptysBio shares tumble after legal fight with GSK over cancer drug license [Yahoo! Finance]
High
Report
AnaptysBio shares tumble after legal fight with GSK over cancer drug license [Yahoo! Finance]
11/21
04:01 am
anab
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary [Yahoo! Finance]
Medium
Report
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary [Yahoo! Finance]
11/21
04:00 am
anab
Anaptys Announces $100 Million Stock Repurchase Plan
High
Report
Anaptys Announces $100 Million Stock Repurchase Plan
11/21
03:50 am
anab
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
High
Report
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
11/20
03:23 am
anab
Assessing AnaptysBio (ANAB) Valuation After Ulcerative Colitis Trial Discontinuation [Yahoo! Finance]
Low
Report
Assessing AnaptysBio (ANAB) Valuation After Ulcerative Colitis Trial Discontinuation [Yahoo! Finance]
11/16
01:08 am
anab
Low
Report
11/13
07:31 am
anab
AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement [Seeking Alpha]
Low
Report
AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement [Seeking Alpha]
11/11
08:44 am
anab
AnaptysBio (NASDAQ:ANAB) was given a new $70.00 price target on by analysts at Barclays PLC.
Low
Report
AnaptysBio (NASDAQ:ANAB) was given a new $70.00 price target on by analysts at Barclays PLC.
11/11
08:09 am
anab
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $59.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $59.00 to $52.00. They now have a "buy" rating on the stock.
11/10
02:04 pm
anab
AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush.
Low
Report
AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush.
11/10
12:06 pm
anab
AnaptysBio (NASDAQ:ANAB) had its price target raised by analysts at Truist Financial Corporation from $20.00 to $36.00. They now have a "hold" rating on the stock.
Low
Report
AnaptysBio (NASDAQ:ANAB) had its price target raised by analysts at Truist Financial Corporation from $20.00 to $36.00. They now have a "hold" rating on the stock.
11/10
10:01 am
anab
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis [Yahoo! Finance]
Low
Report
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis [Yahoo! Finance]
11/10
09:58 am
anab
AnaptysBio posts mid-stage trial setback for lead asset in ulcerative colitis [Seeking Alpha]
Low
Report
AnaptysBio posts mid-stage trial setback for lead asset in ulcerative colitis [Seeking Alpha]
11/10
09:00 am
anab
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
High
Report
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
11/5
10:07 am
anab
AnaptysBio (NASDAQ:ANAB) had its price target raised by analysts at Wells Fargo & Company from $51.00 to $81.00. They now have an "overweight" rating on the stock.
Low
Report
AnaptysBio (NASDAQ:ANAB) had its price target raised by analysts at Wells Fargo & Company from $51.00 to $81.00. They now have an "overweight" rating on the stock.
11/5
10:06 am
anab
AnaptysBio (NASDAQ:ANAB) had its price target raised by analysts at Guggenheim from $90.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
AnaptysBio (NASDAQ:ANAB) had its price target raised by analysts at Guggenheim from $90.00 to $100.00. They now have a "buy" rating on the stock.
11/4
04:15 pm
anab
Anaptys Announces Participation in November Investor Conferences
Low
Report
Anaptys Announces Participation in November Investor Conferences
11/4
04:15 pm
anab
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
11/1
08:33 am
anab
A Look at AnaptysBio's (ANAB) Valuation Following Promising Phase 2b Rosnilimab Results and Analyst Upgrades [Yahoo! Finance]
Low
Report
A Look at AnaptysBio's (ANAB) Valuation Following Promising Phase 2b Rosnilimab Results and Analyst Upgrades [Yahoo! Finance]